Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18351246 | 0.93 | L3MBTL1 (0.33) | L3MBTL1APPCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16749130 | 0.92 | L3MBTL1 (0.38) | L3MBTL1MAPTATMNPSR1ALDH1A1 | |
| SCHEMBL13483857 | 0.88 | MAPT (0.40) | L3MBTL1MAPTATMNPSR1CYP2C19 | |
| SCHEMBL16749064 | 0.88 | L3MBTL1 (0.37) | L3MBTL1MAPTKDM1AALDH1A1 | |
| SCHEMBL16749128 | 0.85 | L3MBTL1 (0.34) | L3MBTL1KDM1AAPPCYP3A4CYP2D6 | |
| SCHEMBL16749133 | 0.85 | L3MBTL1 (0.34) | L3MBTL1KDM1AALDH1A1 | |
| SCHEMBL20126334 | 0.85 | KDM4E (0.42) | L3MBTL1ATMNPSR1 | |
| SCHEMBL16749127 | 0.83 | SLC6A2 (0.32) | L3MBTL1CYP2D6 | |
| SCHEMBL20126357 | 0.82 | RARB (0.37) | L3MBTL1MAPTATMNPSR1ALDH1A1 | |
| SCHEMBL16749047 | 0.82 | KDM1A (0.39) | L3MBTL1MAPTNPSR1KDM1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265343-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT | JNC CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265343-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT | JNC CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20200270525-A1 | LIQUID CRYSTAL COMPOSITION AND LIGHT SWITCHING DEVICE | JNC CORPORATION (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200199451-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-06-25 | — | — | US | disclosed |
| US-10053425-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-08-21 | — | — | US | disclosed |
| US-9969935-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9969935-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160376505-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160289189-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289189-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289189-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-3072885-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015076077-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC株式会社 | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376505-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | VCL, LASP1, NLK | L3MBTL1 376/4885MAPT 27/4885ATM 1738/4885 |
| US-10053425-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | PLD1, DRD1, PLD2 | L3MBTL1 671/4885MAPT 2799/4885ATM 3987/4885 |
| US-20160289189-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | PLD1, DRD1, CCND1 | L3MBTL1 878/4885MAPT 3013/4885ATM 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.